![](images/graphics/blank.gif)
T790M mutation
-
We aimed to identify the T790M mutation rate and clinical factors predicting the occurrence of acquired T790M mutations in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after first- and secondgeneration tyrosine kinase inhibitor (TKI) treatment.
9p
vicarlos
16-05-2024
1
0
Download
-
Many previous studies have demonstrated that minor-frequency pretreatment T790M mutation (preT790M) could be detected by ultrasensitive methods in a considerable number of treatment-naïve, epidermal growth factor receptors (EGFR)-mutated, non-small cell lung cancer (NSCLC) cases.
11p
vikolindagrabar
27-07-2022
5
1
Download
-
The clinical features, survival outcomes and patterns of treatment failure of advanced non-small cell lung cancer (NSCLC) patients harboring distinct subtypes of EGFR mutations and receiving first-line EGFR tyrosine kinases inhibitor (TKIs) are not fully understood.
11p
vipriyankagandhi
27-07-2022
3
1
Download
-
Although with the impressive efficacy, several patients showed intrinsic resistance or an unsatisfactory response to Osimertinib. We aim to explore the impact of clinical and molecular features on efficacy and outcome of patients with EGFR T790M-mutation non-small cell lung cancer (NSCLC) receiving second-line Osimertinib.
12p
visusanwojcicki
28-06-2022
13
2
Download
-
Osimertinib is a standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Although malignant pleural effusion (PE) is a common clinical problem in NSCLC, information about the efficacy of osimertinib in patients with PE is limited, especially regarding its efficacy in EGFR T790M-negative patients with PE remains unclear.
9p
visusanwojcicki
28-06-2022
12
2
Download
-
In the existing next generation sequencing (NGS) system, epidermal growth factor receptor (EGFR) exon 19 deletion-insertion (19delins) is still interpreted into the category of EGFR exon 19 deletion (19del). However, the controversy exists whether the two mutation types have the similar responses and resistant mechanisms to first-generation EGFR tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC) patients.
9p
vimahuateng
26-11-2021
7
1
Download
-
Nghiên cứu này tiến hành nhằm mục tiêu xác định đột biến kháng thuốc thứ phát T790M trên gen EGFR ở bệnh nhân ung thư phổi không tế bào nhỏ có dấu hiệu kháng thuốc điều trị đích. Kỹ thuật giải trình tự gen trực tiếp và kỹ thuật Scorpions ARMS (Scorpions-Amplification Refractory Mutation System) với độ nhạy cao được áp dụng đề xác định đột biến.
5p
closefriend02
07-10-2021
25
1
Download
-
AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to describe the experience with osimertinib in Spain.
12p
vianrose2711
27-04-2021
10
1
Download
-
Cell-free DNA (cfDNA) genotyping in plasma using the cobas EGFR Mutation Test v2 (cobas) is the first liquid biopsy as a companion diagnosis to identify the EGFR T790M mutation (T790M) after the failure of treatment of EGFR-tyrosine kinase inhibitors (TKIs) (1st generation, gefitinib [G] and erlotinib [E] and 2nd generation, afatinib [A]).
9p
vianrose2711
27-04-2021
12
1
Download
-
Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have become the standard care of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), development of acquired resistance is inevitable.
8p
vimale2711
25-08-2020
10
2
Download
-
The majority of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation eventually develop resistance to EGFR tyrosine kinase inhibitors (TKIs). Minimal information exists regarding genetic alterations in rebiopsy samples from Asian NSCLC patients who develop acquired resistance to EGFR-TKIs.
8p
vimale2711
25-08-2020
11
2
Download
-
Lung cancer patients with an activating mutation in the EGFR (epidermal growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated by the T790M resistance mutation in EGFR. The difficulties in obtaining biopsies at progression make it challenging to investigate the appearance of the T790M mutation at progression in large patient cohorts.
5p
vibaku2711
22-07-2020
14
2
Download
-
To describe the clinical and subclinical features of lung cancer patients with EGFR mutations before TKIs therapy and in the relapsed period. To identify the T790M mutation and MET amplification in patients with lung cancer and EGFR-TKIs resistance and the relationship with clinical and subclinical features.
29p
cothumenhmong6
17-07-2020
8
1
Download
-
Osimertinib, the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has become the standard treatment in cases where rebiopsy reveals T790M mutation after the first-line EGFR-TKI treatment.
5p
viputrajaya2711
22-06-2020
17
0
Download
-
The EGFR-T790M mutation is clinically detected using re-biopsy in approximately 50% of patients with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small cell lung cancer (NSCLC) who harbor EGFR mutations.
6p
viputrajaya2711
22-06-2020
20
0
Download
-
Non - small cell lung cancer (NSCLC) is the largest subgroup of lung cancers, responsible for about 80% of all lung cancers. Targeted cancer therapy has opened a new window into treatment of non - small cell lung cancer. This therapy is very effective for patients who have EGFR (Epidermal growth factor receptor) activating mutations, primarily located in the tyrosine kinase domain in the form of a base - pair deletion at exon 19 (LREA deletions, accounting for about 54%) or a point mutation at exon 21 (L858R, accounting for about 43%).
9p
quenchua1
04-11-2019
11
0
Download
-
Nghiên cứu này tiến hành nhằm mục tiêu xác định đột biến kháng thuốc thứ phát T790M trên gen EGFR ở bệnh nhân ung thư phổi không tế bào nhỏ có dấu hiệu kháng thuốc điều trị đích. Kỹ thuật giải trình tự gen trực tiếp và kỹ thuật Scorpions ARMS (Scorpions - Amplification Refractory Mutation System) với độ nhạy cao được áp dụng để xác định đột biến.
8p
sieunhansoibac5
18-04-2018
55
1
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)